Get Live Data

The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. ARIX.L Share Price
  4. ARIX.L Share Regulatory News
  5. PDMR Notification & Director Shareholding

Pin to quick picksARIX.L Regulatory News (ARIX)

ARIX.L Information
  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Notification & Director Shareholding

3 Nov 2023 16:30

Arix Bioscience PLC (ARIX) PDMR Notification & Director Shareholding 03-Nov-2023 / 16:30 GMT/BST

Arix Bioscience plc("Company")

PDMR Notification & Director Shareholding

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 40,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 3rd November 2023 at a price of £1.15 per share.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Peregrine Moncreiffe

2

 

Reason for the notification

 

a)

 

Position/status

 

 Non-Executive Director and Chair of the Board

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

c)

Price(s) and volume(s)

 

Price(s)£

Volume(s)

 

 

 

1.15

40,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

40,000

- Price

£46,000.00

e)

 

Date of the transaction

 

3 November 2023

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact: Kin Company Secretarial Limited, Company Secretary+44 20 8819 6486

Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:DSH
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:282725
EQS News ID:1765125
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

3456789101112
Date   Source Headline
31st Mar 20215:39 pmEQSTransaction in own shares
30th Mar 20215:09 pmEQSTransaction in own shares
30th Mar 20211:02 pmEQSArix leads $152 million Series B financing for Pyxis Oncology
30th Mar 20217:00 amEQSGita Dittmar appointed as Venture Partner
29th Mar 20215:14 pmEQSTransaction in own shares
29th Mar 20217:00 amEQSBoard update
26th Mar 20215:14 pmEQSTransaction in own shares
25th Mar 20214:58 pmEQSTransaction in own shares
24th Mar 20215:05 pmEQSTransaction in own shares
24th Mar 20217:00 amEQSStrategy Implementation Review
23rd Mar 20215:27 pmEQSTransaction in own shares
22nd Mar 20215:57 pmEQSTransaction in own shares
22nd Mar 202111:09 amEQSAura Biosciences announces oversubscribed $80 million financing
22nd Mar 20217:00 amEQSShare buyback programme of up to £25 million
19th Mar 20214:00 pmEQSHolding(s) in Company
15th Mar 20217:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): 32% IRR since inception in 2016
15th Mar 20217:00 amEQSShare buyback programme of up to £25 million
10th Mar 20217:01 amEQSResponse to Activist Shareholder Acacia
9th Mar 20217:01 amEQSArix founds new portfolio company Twelve Bio
9th Mar 20217:01 amEQSAnnual Results for the Twelve Months ended 31 December 2020
25th Feb 20217:00 amEQSBoard Changes
15th Feb 20219:00 amEQSHolding(s) in Company
11th Feb 20217:00 amEQSNotice of Results
10th Feb 20219:00 amEQSAutolus announces pricing of public offering
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20219:06 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
18th Jan 20217:00 amEQSInvestment team changes
12th Jan 20217:00 amEQSHarpoon announces closing of public offering
6th Jan 20212:00 pmEQSImara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease  
6th Jan 202110:00 amEQSAutolus provides business outlook for 2021 and 2022
31st Dec 20209:00 amRNSPrice Monitoring Extension
21st Dec 20207:00 amEQSDirector Share Purchase
18th Dec 20208:00 amEQSCompletion of sale of VelosBio
11th Dec 20207:00 amEQSAtox Bio announces FDA acceptance of New Drug Application
8th Dec 20203:45 pmEQSHarpoon reports clinical progress across all pipeline development programmes
7th Dec 20205:48 pmEQSAutolus presents additional data on AUTO3 at ASH
7th Dec 20207:15 amEQSHardman & Co Research: Arix Bioscience (ARIX): Artios attracts Merck KGaA in deal up to $7bn
7th Dec 20207:01 amEQSAutolus presents positive AUTO1 data at ASH
4th Dec 20207:01 amEQSHolding(s) in Company
4th Dec 20207:00 amEQSHolding(s) in Company
3rd Dec 20209:05 amRNSSecond Price Monitoring Extn
3rd Dec 20209:00 amRNSPrice Monitoring Extension
3rd Dec 20208:01 amEQSArtios and Merck KGaA announce global strategic collaboration
12th Nov 20207:00 amEQSArix to Present at the Jefferies Virtual London Healthcare Conference
6th Nov 202012:10 pmEQSHardman & Co Research: Arix Bioscience (ARIX): Hitting the jackpot
5th Nov 20202:06 pmRNSSecond Price Monitoring Extn
5th Nov 20202:00 pmRNSPrice Monitoring Extension
5th Nov 202011:38 amEQSArix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion
3456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.